This year, the second General Assembly (GA) took place in Paris (France) on June 19th-20th, 2015 with the participation of the whole GAPP Consortium.
The meeting provided an update on the achievements and difficulties encountered toward the implementations of specific project tasks, the reasons for some delays and the mitigation strategies set into place in order to overcome such obstacles, and dedicated specific session to the steps necessary for the implementation of the clinical studies.
With this specific aim, divided into six thematic sessions, the meeting allowed to address various aspects and issues of the gabapentin clinical development, such as protocols’ challenges and procedures, data management, clinical operations, dissemination and communication strategies as well as all the ethics and regulatory aspects.
The meeting represented an excellent opportunity to foster fruitful scientific debates and networking and to set project priorities. Indeed, it provided a great opportunity for exchanging information while discussing advancement in the work packages and partners’ involvement, in order to build up a perfect working basis for the forthcoming activities.
